Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS
Open Access
- 30 April 2021
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (8), 1678-1685
- https://doi.org/10.1111/jdv.17332
Abstract
Background Basal cell carcinoma (BCC) can arise by the uncontrolled proliferation of cells from multiple epidermal compartments due to aberrant activation of the Hedgehog (Hh) signaling pathway. Vismodegib, a small‐molecule inhibitor of this pathway, is approved for treatment of patients with locally advanced (la) BCC inappropriate for surgery or radiotherapy or patients with symptomatic metastatic (m) BCC. Objectives The aim of this non‐interventional study was to assess effectiveness with a special focus on duration of response (DOR), safety and utilization of vismodegib for treatment of laBCC in daily practice in Germany. Methods This non‐interventional study (NIS) observed treatment of laBCC with vismodegib according to the German label in clinical practice. All available patients who had received at least one dose of vismodegib between commercial availability of vismodegib in Germany (02 August 2013) and 3 years before end of study (31 March 2016) could be included and were documented retrospectively and/or prospectively for up to 3 years. Primary effectiveness variable was DOR. Assessment of tumor response was carried out by the treating physicians. Exploratory variables included utilization of vismodegib, decision makers for therapy and method of tumor response evaluation. All statistical analyses were descriptive. Results Between September 2015 and March 2019, 66 patients were observed at 26 German centers. The objective response rate (ORR) was 74.2% and the disease control rate (DCR) was 90.9%. The median DOR was 15.9 months (95% CI: 9.2; 25.7; n=49 patients with response).The median progression‐free survival (PFS) was 19.1 months and the median time to response (TTR) 2.7 months. A total of 340 adverse events were reported in 63 (95.5%) patients; no new safety signals were identified. Conclusions The NIS NIELS shows effectiveness and safety of vismodegib in patients with laBCC. It confirms the transferability of the results of the pivotal trial into routine clinical practice.Keywords
This publication has 22 references indexed in Scilit:
- Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of diseaseEuropean Journal of Cancer, 2014
- Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegibJournal of the American Academy of Dermatology, 2014
- Non-Melanoma Skin Cancer Incidence and Impact of Skin Cancer Screening on IncidenceJournal of Investigative Dermatology, 2014
- Update on Metastatic Basal Cell Carcinoma: A Summary of Published Cases From 1981 Through 2011JAMA Dermatology, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaThe New England Journal of Medicine, 2012
- New Concepts for Basal Cell Carcinoma. Demographic, Clinical, Histological Risk Factors, and Biomarkers. A Systematic Review of Evidence Regarding Risk for Tumor Development, Susceptibility for Second Primary and RecurrenceJournal of Surgical Research, 2010
- The role of the human homologue of Drosophila patched in sporadic basal cell carcinomasNature Genetics, 1996
- Human Homolog of patched , a Candidate Gene for the Basal Cell Nevus SyndromeScience, 1996
- Nevoid Basal-Cell Carcinoma SyndromeMedicine, 1987
- Metastatic basal cell carcinoma: Report of five cases and review of 170 cases in the literatureJournal of the American Academy of Dermatology, 1984